Literature DB >> 33940026

Novel chitosan-coated niosomal formulation for improved management of bacterial conjunctivitis: A highly permeable and efficient ocular nanocarrier for azithromycin.

Hussein M Eid1, Ibrahim A Naguib2, Reem I Alsantali2, Izzeddin Alsalahat3, Amira M Hegazy4.   

Abstract

In the present study, we aimed to formulate, optimize, and characterize azithromycin chitosan coated niosomes (AZM-CTS-NSM) as a novel colloidal system that increases precorneal residence period, eye permeation, and bioavailability. AZM-NSM was formulated via a modified thin-film hydration strategy and then coated with CTS. We assessed the influence of the cholesterol: surfactant molar ratio, CTS concentration, and surfactant type on particle diameter, entrapment, zeta potential, and NSM adhesion force to the corneal mucosal membrane and employed a central composite design (CCD). The resulting optimized AZM-CTS-NSM has a mean diameter of 376 nm, entrapment of 74.2%, surface charge of 32.1 mV, and mucoadhesion force of 3114 dyne/cm2. The optimized AZM-CTS-NSM demonstrated a prolonged in vitro release behavior. When compared with commercial eye drops, the optimized AZM-CTS-NSM produced a 2.61-fold increase in the apparent permeability coefficient, significantly improving corneal permeability. Additionally, ocular irritation was assessed, with no major irritant effects found to be induced by the formulated NSM. Compared with AZM commercial drops, the optimized AZM-CTS-NSM revealed ˃ 3-fold increase in AZM concentration in the rabbit eyes. Collectively, these findings indicate that CTS-NSM is a potentially valuable ocular nanocarrier that could augment the efficacy of AZM.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Azithromycin; Bioadhesion; Chitosan; LC-MS; Niosomes; Ocular drug delivery; Ocular permeation; Sustained drug release

Year:  2021        PMID: 33940026     DOI: 10.1016/j.xphs.2021.04.020

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Potential Use of Tailored Citicoline Chitosan-Coated Liposomes for Effective Wound Healing in Diabetic Rat Model.

Authors:  Hussein M Eid; Adel A Ali; Ahmed M Abdelhaleem Ali; Essam M Eissa; Randa M Hassan; Fatma I Abo El-Ela; Amira H Hassan
Journal:  Int J Nanomedicine       Date:  2022-02-05

Review 2.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

3.  Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats.

Authors:  Mohammed H Elkomy; Hussein M Eid; Mohammed Elmowafy; Khaled Shalaby; Ameeduzzafar Zafar; Mohamed A Abdelgawad; Mostafa E Rateb; Mohammed R A Ali; Izzeddin Alsalahat; Heba A Abou-Taleb
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Intranasal Delivery of Granisetron to the Brain via Nanostructured Cubosomes-Based In Situ Gel for Improved Management of Chemotherapy-Induced Emesis.

Authors:  Essam M Eissa; Mohammed H Elkomy; Hussein M Eid; Adel A Ali; Mohammed A S Abourehab; Amal M Alsubaiyel; Ibrahim A Naguib; Izzeddin Alsalahat; Amira H Hassan
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

5.  Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route.

Authors:  Hadel A Abo El-Enin; Mohammed H Elkomy; Ibrahim A Naguib; Marwa F Ahmed; Omar A Alsaidan; Izzeddin Alsalahat; Mohammed M Ghoneim; Hussein M Eid
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-24

6.  Surface-Modified Bilosomes Nanogel Bearing a Natural Plant Alkaloid for Safe Management of Rheumatoid Arthritis Inflammation.

Authors:  Mohammed H Elkomy; Nabil K Alruwaili; Mohammed Elmowafy; Khaled Shalaby; Ameeduzzafar Zafar; Naveed Ahmad; Izzeddin Alsalahat; Mohammed M Ghoneim; Essam M Eissa; Hussein M Eid
Journal:  Pharmaceutics       Date:  2022-03-03       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.